Kornimate/medical-research-clean huggingface dataset:
bone marker changes with teriparatide/postmenopausal osteoporosis

Conditions: Osteoporosis, Post-Menopausal

Summary: to test the hypothesis that teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population


Eligibility criteria:
inclusion criteria: * presents with severe osteoporosis based on the disease diagnostic criteria and upon physician assessment * postmenopausal, nonpregnant, women older than 50 years of age, with previous fracture history such as hip, spine, wrist, ribs, clavicle, humerus, tibia, and fibula or men over 50 years of age with low impact fractures (fragility). * outpatients without concomitant diseases and with life expectancy of at least 3 years, according to the medical criteria. * cannot be on medicines that can disturb bone metabolism. * patients should be capable of self-injection, to learn the use of pen device and are in agreement with its use. exclusion criteria: * directly affiliated with the conduct of this study, or are the immediate family of someone directly affiliated with the conduct of this study (that is, lilly employees, investigators, site personnel, or their immediate families). immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry. * previously completed or withdrawn from this study or any other study investigating teriparatide. * secondary osteoporosis or any disease that affects the bone metabolism, as renal osteodystrophy, osteomalacia, hypoparathyroidism, and hyperparathyroidism, and intestinal malabsorption. * cancer history in the 5 years prior to visit 1, with exemption of basocellular carcinoma treated and cervix carcinoma definitively treated at least 1 year before to visit 1
managing non-acute subdural hematoma using liquid materials：a chinese randomized trial of mma treatment

Conditions: Subdural Hematoma, Non-acute

Summary: magic-mt study is multi-center, prospective, randomized (1:1) controlled trial designed to show that additional mma embolization with onyx in patients with non-acute symptomatic subdural hematoma(sdh) results in reduced hematoma recurrence in surgically treated patients/ reduced hematoma progression in conservatively managed patients.

the objective of this study is to show that additional mma embolization with onyx in patients with non-acute symptomatic subdural hematoma(sdh) results in reduced hematoma recurrence in surgically treated patients/ reduced hematoma progression in conservatively managed patients.

Eligibility criteria:
inclusion criteria: 1. patients with symptomatic non-acute sdh with mass effect (i.e., chronic or subacute sdh) 1. mass effect refers to a shift in midline structure or deformation of local cerebral cortex due to sdh. 2. symptomatic defined as neurological symptoms, such as headache, short-term cognitive dysfunction, language disorder or aphasia, gait instability, decreased muscle strength, sensory disturbances, epileptic seizure, etc. 2. age ≥18 years; 3. pre-morbid mrs score 2; 4. informed consent form (icf) signed by patient or guardian. exclusion criteria: 1. radiographic imaging indicating massive cerebral infarction with corresponding symptoms; 2. required craniotomy or craniotomy with small bone flap to remove sdh; 3. emergency sdh removal/drainage; 4. bilateral sdh with unknown origin of symptoms; 5. anatomical variations that may affect the safety of mma embolization (e.g., prominent middle mma-ophthalmic artery anastomosis); 6. intractable coagulation dysfunction or abnormal platelet count and function (pre-operative international normalized ratio \[inr\] \> 1.5 and/or platelet count \< 80109/l); 7. contraindications to cerebral angiography, such as allergy to iodinated contrast agents, renal insufficiency (gfr \< 30 ml/min), etc.; 8. computed tomography (ct) or magnetic resonance imaging (mri) showing intracranial space-occupying lesions; 9. pregnancy or planning to become pregnant; 10. serious or fatal coexisting disease that may prevent improvement of conditions or completion of follow-up; 11. life expectancy \< 1 year; 12. recent operation unrelated to this study or investigators believe that they will be at higher risks if antiplatelet and/or anticoagulant drugs are discontinued; 13. inability to complete follow-up as required by the protocol; 14. patients participating in other clinical trials; 15. prior surgery or interventional therapy on target sdh; 16. inability to complete mma embolization before trepanation and drainage.
tolterodine relieves overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome

Conditions: Overactive Bladder; Obstructive Sleep Apnea; Overactive Bladder Syndrome

Summary: in this study, we aim to determine whether combined tolterodine and cpap therapy is a more effective treatment for patients with osas than cpap treatment only.


Eligibility criteria:
inclusion criteria: * women older than 18 who underwent polysomnography test with suspicion of osas between 01.06.2020-01.01.2022 were enrolled in the study * patients with ahi ≥15 (moderate or severe) and oab-v8≥8 were considered eligible for the study and randomized in two groups to receive either cpap treatment only or cpap treatment with tolterodine tartrate exclusion criteria: * patients diagnosed with neurological diseases, diabetes mellitus, congestive heart failure, infection, hematuria, urolithiasis, urinary tumors, and urinary retention were excluded from the study. also, a history of lower urinary tract surgery and medication due to lower urinary tract symptoms were the exclusion criteria.
can we forget? directed forgetting and embodied cognition in schizophrenia

Conditions: Schizophrenia

Summary: based on the theory of embodied cognition, which focuses on the influence of sensory and motor processes on cognition, researchers propose to study the influence of the action on memorization and inhibition in patients suffering from schizophrenia, using a directed forgetting paradigm. the directed forgetting paradigm is used, composed of two lists of action verbs. the instruction "to forget" is given at the end of learning the first list (to be forgotten (tbf)), following a simulation of a computer bug. therefore a second list is presented to be learned and remembered (to be remembered (tbr)). a recognition task is performed at the end. the action verbs had to be encoded using four conditions: action performed, mimed, imagined action, action with a contextual word, reading the action verb only. 48 schizophrenic patients were included in this study. patients were randomized to have 10 participants per condition. 48 controls matched by age, gender, laterality and education are also included and randomized in the same modality. this study aims to show that the encoding of sensory-motor components, more than providing a context could improve the inhibitory capacities but also memory in schizophrenia, and possibly be used in remediation cognitive.

researchers used the directed forgetting paradigm composed of two lists of action verbs. the instruction "to forget" is given at the end of learning the first list (to be forgotten (tbf)), following a simulation of a computer bug. therefore a second list is presented to be learned and remembered (to be remembered (tbr)). a recognition task is performed at the end. the action verbs had to be encoded using four conditions: action performed, mimed, imagined action, action with a contextual word, reading the action verb only. 48 schizophrenic patients were included in this study. patients were randomized to have 10 participants per condition. 48 controls matched by age, gender, laterality and education are also included and randomized in the same modality. this study aims to show that the encoding of sensory-motor components, more than providing a context could improve the inhibitory capacities but also memory in schizophrenia, and possibly be used in remediation cognitive.

Eligibility criteria:
inclusion criteria for patients: * schizophrenic patients as defined in diagnostic and statistical manual of mental disorders iv (dsm-iv) * stabilized a therapeutic point of view for at least one month. * consent form signed * affiliated to a security health program inclusion criteria for volunteers: * consent form signed * affiliated to a security health program exclusion criteria for patients and volunteers : * not having a history of head trauma, neurological disease or not stabilized serious somatic illness, * not to use psychoactive substance, as defined by the dsm iv. * the intelligence quotient must not be less than 70 (progressive matrices standard score (pm38), raven progressive matrix).

Keywords: schizophrenia memory cognition
evaluating patient knowledge about perioperative neurocognitive disorders (know-pnd study)

Conditions: Anesthesia Complication

Summary: neurocognitive disorders remain one of the major perioperative complications. they are associated with delayed recovery, prolonged length of hospital stay and impacts on patients' quality of life. the incidence of pnd ranges from 15-50%. while several causes have been investigated, pnd seems to be due to the non-resolution of an inflammatory cascade, making some patients more at risk than others. as such, major risk factors include old age and lower education levels. as the global proportion of people aged 60 and above between 2015 and 2050 will increase from 12% to 22% and worldwide surgeries increases to \>300 million procedures per annum the incidence of perioperative neurocognitive disorders with high morbidity and mortality will go up. in 2015, the american society of anesthesiologists (asa) launched the 'perioperative brain health initiative' to increase awareness about perioperative neurocognitive disorders. (pnd) while physicians seems to be more and more aware about this condition, data regarding patient awareness are not available. an observational, single-centre, cross-sectional survey study (with initially a feasibility study) will be conducted in patients, 65 years and above undergoing elective total hip replacement surgery at az sint-jan (brugge, belgium) to assess patients' basic knowledge regarding pnd.


Eligibility criteria:
inclusion criteria: * age 65 and above * asa score 1 to 3 * scheduled for elective hip surgery. exclusion criteria: * insufficient knowledge of dutch * known neuropsychiatric conditions
the effect effect of empagliflozin on oxidative stress in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes. the association is examined by comparing the difference in oxidative modifications before and after 14 days treatment with 25 mg empagliflozin compared to placebo treatment. the study is randomised, double-blinded, and placebo controlled. each treatment group consists of 17 males with type 2 diabetes. oxidative modifications are measured by urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine and 8-oxo-7,8-dihydroguanosine. a student t-test will be performed to compare the drug treatment with placebo. the results will be published in a peer-review journal.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes * hba1c: 6.5-9.0% * capable of understanding oral- and written information * caucasian exclusion criteria: * estimated glomerular filtration rate (egfr) \< 60 ml/hour/1.73 m2 * currently receiving insulin treatment * coronary artery bypass grafting, percutaneous coronary intervention, acute coronary syndrome, stroke, lung embolism, deep vein thrombosis, or transitory cerebral ischemia within 6 months * genital infection within 14 days * plasma alanine aminotransferase ≥3 times upper normal limit * treatment with sodium glucose cotransporter (sglt) -2 inhibitor within 2 months * hyperglycaemic symptoms * psychiatric disorder * intolerance to empagliflozin or other agents relevant to study * non-compliant

Keywords: empagliflozin oxidative stress oxidative nucleic acid modifications 8-oxo-7,8-dihydro-2'-deoxyguanosine 8-oxo-7,8-dihydroguanosine
effect of short-term annatto carotenoids supplementation on oxidative stress status in healthy individuals

Conditions: Oxidative Stress; Atherosclerosis

Summary: low-density lipoprotein (ldl) oxidation has a pivotal role in atherosclerosis development. there is a relationship between carotenoids serum concentration and cardiovascular (cv) benefits, mainly in oxidized ldl (oxldl) reduction. despite cardio protective effects of annatto carotenoids, bixin and norbixin, in vitro and in animal studies, its short or long-term supplementation effect on humans are not know. objective: to analyse cv benefits of annatto carotenoids short-term supplementation in healthy individuals, comparing to lycopene effect. methods: 16 healthy volunteers (8 men and 8 women) consumed 0.05 mg/kg b.w. of each treatment (bixin, norbixin, lycopene or placebo) through capsules, during 7 days. it was analysed the susceptibility of ldl to cu2+-induced oxidation, biochemical parameters and oxidative stress biomarkers at the beginning and end of each treatment.

graduate and post-graduate students were recruited in federal university of santa maria to study participation. first, the health status of volunteers was analysed by questioner application (to evaluate lifestyle, family history, individual characteristics), anthropometric (height, weight, waist circumference) and biochemical parameters (glucose, lipid profile, transaminases, urea, creatinine) measurements. according to inclusion criteria, 18 volunteers were able to study participation, but just 16 people remained until the end of the study. each treatment was composed by 7 capsules (containing 0.05 mg carotenoid or placebo/kg b.w.) which should be consumed once a day (preferably in the morning), during 7 days. it was conducted a randomized, double blind, placebo-controlled crossover clinical trial, where 16 participants received 4 proposed treatments (bixin, norbixin, lycopene and placebo) in different periods. to plasma, serum and red blood cells (rbc) obtainment, 2 fasting blood collections were made, in the beginning (day 0) and the end (day 7) of each treatment. these samples were used for evaluating the ex vivo oxidation of ldl induced by copper sulphate and biochemical and oxidative biomarkers measurements.

Eligibility criteria:
inclusion criteria: * normal levels of glucose, lipid profile, transaminases, urea and creatine * normal blood pressure, weight and body mass index (bmi) exclusion criteria: * chronic diseases (diabetes, dyslipiademia, hypertension cancer, etc.) * drug, alcohol and cigarette consumption/addiction * medication, vitamins or suplements consumption (except oral contraceptive used by women) * recent inflammatory/infectious diseases

Keywords: carotenoid ldl oxidation cardiovascular disease antioxidant
hyperpolarized xenon-129 mri in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. the investigator hypothesize hyperpolarized xe129-mri can be performed in patients with ipf and repeated over time which will detect deficiencies related to perfusion in the lung.

idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. idiopathic pulmonary fibrosis (ipf) is a subtype of interstitial lung disease (ild) that can lead to chronic hypoxic and ventilatory respiratory failure and early death.1 while current treatments slow disease progression, they do not improve symptoms or quality of life and are often poorly tolerated due to significant side effect profiles. therefore, there remains an unmet need for more tolerable therapies with an acceptable side effect profile that slows progression and improves patient-centered outcomes. functional imaging is a promising tool for assessing treatment response in ipf. longitudinal decline in forced vital capacity (fvc) and time-to-event outcomes like hospitalization and death have been traditional clinical trial endpoints in ipf. however, these endpoints are time and resource-consuming. thus, there has been significant interest in using other trial endpoints, the most promising of which is lung imaging. the study group employed hyperpolarized xenon-129 magnetic resonance imaging (xe129-mri) to quantify and localize deficits in pulmonary ventilation and perfusion in chronic obstructive diseases. it has recently extended this to pulmonary fibrosis. however, to implement xe129-mri as an endpoint in a mechanistic clinical trial, the investigator proposes to demonstrate the feasibility of employing this procedure over time in patients with ipf. the investigator hypothesizes that hyperpolarized xe129-mri can be performed in patients with ipf and repeated over time, which will detect deficiencies related to perfusion in the lung.

Eligibility criteria:
inclusion criteria: * able to provide informed consent 18 years of age or greater clinical diagnosis of ipf exclusion criteria: * continuous oxygen use at home * oxygen saturation less than 92% on the day of mri procedure * pregnancy or lactation * claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to mr scanning. subjects with any implanted device that cannot be verified as mri compliant will be excluded. * history of congenital cardiac disease, chronic renal failure, or cirrhosis. • chest circumference greater than that of the xenon mr and/or helium coil. the circumference of the coil is approximately 42 inches. * inability to understand simple instructions or to hold still for approximately 10-15 seconds. * history of respiratory infection within 2 weeks prior to the mr scan * history of mi, stroke and/or poorly controlled hypertension.

Keywords: hyperpolarized xenon-129 gas with mri
impact of cataract surgery on keratoplasty graft survival

Conditions: Cataract; Fuchs' Endothelial Dystrophy; Keratoconus

Summary: the follow up time after keratoplasty now routinely exceeds multiple decades. it is common for keratoplasty patients to also undergo cataract surgery at a later date in their lives. keratoplasties and cataract surgery both result in local inflammation. this may influence the density of endothelial cells, and on average there is a loss of 10% in endothelial cells within 3 months of the cataract surgery. yet, a sufficient density of endothelial cells is required to maintain graft transparency. it may be therefore difficult to strike a balance between loss of visual acuity due to the cataract of to the loss of graft transparency over the long term. the investigators aim to compare graft survival in patients with clear crystalline lens with and without cataract surgery.


Eligibility criteria:
inclusion criteria: * all patients undergoing keratoplasty * between january 1983 and december 2012 * age 40 and older at the time of surgery exclusion criteria: * cataract surgery prior to the keratoplasty * systemic inflammatory disease * previous history of uveitis

Keywords: corneal transplantation graft survival
serial electrophysiologic monitoring during administration of nerve-toxic chemotherapeutic drugs

Conditions: Chemotherapy; Nerve Degeneration; Nerve Conduction

Summary: the study hypothesis is that changes in serially obtained nerve conduction study data obtained every 3-4 weeks in cancer patients receiving chemotherapy can be used to predict the development of a clinically significant / disabling drug induced neuropathy six and twelve months following the start of treatment. patients with breast cancer, colon cancer, gastroesophageal cancer, and non-hodgkins lymphoma will be enrolled. six lower extremity nerves--three in each leg--will be electrically stimulated and their responses recorded at three to four week intervals coinciding with patient's scheduled chemotherapy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of untreated breast cancer, treated (advance stage) or untreated colon cancer, untreated non-hodgkins lymphoma, or advanced gastroesophageal cancer scheduled to begin chemotherapy with either taxol, oxaliplatin, or vincristine exclusion criteria: * individuals with an implanted electronic medical devices (cardiac pacemaker or defibrillator, vagus nerve stimulator, deep brain stimulator, intrathecal pump, others) * individuals whose chemotherapy regimen will include nerve toxic drugs other than taxol, oxaliplatin, or vincristine, or includes more than one of these three drugs in combination * individuals whose screening nerve conduction studies show peroneal motor amplitude \< 1 mv bilaterally or sural sensory amplitude \< 3 uv bilaterally or no result obtainable

Keywords: taxol vincristine oxaliplatin chemotherapy nerve degeneration nerve conduction cancer nerve conduction studies
ph ii trial of a novel anti-angiogenic agent in combination with chemotherapy for the second-line treatment of metastatic colorectal cancer

Conditions: Colorectal Cancer (CRC)

Summary: the purpose of this study is to determine the efficacy of ct-322 comparative to bevacizumab, both in combination with irinotecan, 5-fu and leucovorin in the second-line treatment of subject with metastatic colorectal cancer


Eligibility criteria:
inclusion criteria: * ecog performance status (ps) ≤1 * histologically or cytologically confirmed, unresectable metastatic colorectal cancer * measurable disease by recist guidelines * evidence of disease progression following first-line therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab (≤ 8 weeks since last dose) * available paraffin embedded tumor tissue * willing to give a whole blood sample for the study of proteins and genetic polymorphisms exclusion criteria: * less than 28 days elapsed since major surgery at time of randomization * known cns metastases * excessive risk of bleeding (including use of therapeutic anticoagulation other than low dose aspirin) and history of thrombotic or embolic cerebrovascular accident * uncontrolled hypertension * clinically significant cardiovascular disease * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis * known hiv positive